Prøve GULL - Gratis
Principles and applications of Chromatography & HPLC
Chronicle Pharmabiz
|September 18, 2025
HIGH-performance liquid chromatography (HPLC) is an important instrument used in the pharmaceutical industry for evaluations and quality control of a large variety of samples.
It is a chromatographic method that is used to separate a mixture of compounds in analytical chemistry, biochemistry and especially in pharmaceutical industries so as to identify, quantify or purify the individual components of the mixture. It is a method of choice for checking purity of new chemical entities, monitoring changes in synthetic procedures or scale up, evaluating new formulations, and carrying out quality control and the assurance of the final drug product. The present article gives a brief overview of modern HPLC method development especially for pharma industry.
Rapid high-performance liquid chromatography method could improve formulation quality control studies. Researchers say the novel high-performance liquid chromatography with diode-array detection method can be utilised in routine quality control analysis of levofloxacin in pharmaceutical formulation and bioequivalence studies.
Chromatography and HPLC
Selectivity and detectability optimization are the primary goals in HPLC separations. The separation principle of HPLC is based on the distribution of the analyte (sample) between a mobile phase; called eluent and a stationary phase; usually the packing material of the column, which is stationery. Depending on the chemical structure of the analyte, the molecules are retarded while passing the stationary phase.
In gas chromatography (GC), the mobile phase is a gas and the analytes need to have sufficient volatility to pass through the column. In addition, the analytes need to be stable at the temperatures exposed to in the injector and/or in the column. Analytes that are not volatile, for example, fatty acids, can be made volatile by derivatization, e.g., the fatty acids can be converted to esters.
Denne historien er fra September 18, 2025-utgaven av Chronicle Pharmabiz.
Abonner på Magzter GOLD for å få tilgang til tusenvis av kuraterte premiumhistorier og over 9000 magasiner og aviser.
Allerede abonnent? Logg på
FLERE HISTORIER FRA Chronicle Pharmabiz
Chronicle Pharmabiz
Biocon gets US FDA nod for Bosaya & Aukelso
BIOCON Biologics, a fully integrated global biosimilars company and subsidiary of Biocon has received the US Food and Drug Administration (FDA) approval for Bosaya (denosumab-kyqq) 60 mg/mL injection for subcutaneous use in a single dose prefilled syringe (PFS), and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial, biosimilars of Prolia and Xgeva respectively.
1 mins
September 25, 2025
Chronicle Pharmabiz
Centre to appoint 49 drug inspectors in CDSCO
THE Union Ministry of Health and Family Welfare has notified recruitment of 49 drug inspectors under the Central Drugs Standard Control Organisation (CDSCO), as part of strengthening the organisation's operations to regulate and monitor the drugs and pharmaceutical industry and market in the country.
1 min
September 25, 2025
Chronicle Pharmabiz
Cold Chain Community to hold conference in Ahmedabad
IN order to create new opportunities in the pharmaceutical cold chain sector, Cold Chain Community, a knowledge-based business platform powered by the National Accreditation Body for Cold Chain Management (NAB-CCM), will hold one-day conference on November 4, 2025 in Ahmedabad.
1 mins
September 25, 2025
Chronicle Pharmabiz
HC appoints team to conduct inspection on Palamur Bio's facility
THE Delhi High Court (HC) has appointed a three-member inspection team to conduct fresh inspection at the facility of Telan-gana-based preclinical contract research organisation Palamur Biosciences in connection with the allegations raised by the People for the Ethical Treatment of Animals India (PETA India) pertaining to abuse and neglect of animals while carrying out experimentation.
2 mins
September 25, 2025
Chronicle Pharmabiz
Merck gets 2 positive opinions from CHMP for Keytruda
MERCK, known as MSD outside of the US and Canada, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for Keytruda (pembrolizumab), which if approved would be marketed in the European Union (EU) as Keytruda SC.
1 min
September 25, 2025
Chronicle Pharmabiz
Aptar's Enbumyst receives US FDA nod
APTAR Pharma, a global leader in drug delivery and active material science solutions and services, announced that its unidose liquid system is the delivery system for the recent US FDA-approved Enbumyst (Bumetanide nasal spray) 0.5mg by Corstasis Therapeutics.
1 min
September 25, 2025
Chronicle Pharmabiz
Health insurance faces headwinds of escalating medical inflation
HEALTH insurance industry is entering a period of financial stress, driven by two critical factors.
2 mins
September 25, 2025
Chronicle Pharmabiz
NABL, Ladakh Univ team up to enhance lab capabilities
THE National Accreditation Board for Testing and Calibration Laboratories (NABL) and the University of Ladakh have partnered to enhance testing laboratory capabilities, research, and skill development in Ladakh.
1 min
September 25, 2025
Chronicle Pharmabiz
AICDF blows whistle on drug cos in U'khand
IN a bold move that could shake the pharmaceutical sector, the All India Chemists and Distributors Federation (AICDF) has submitted a scathing complaint to the National Pharmaceutical Pricing Authority (NPPA), raising serious concerns over the activities of certain drug manufacturers operating out of Uttarakhand.
2 mins
September 25, 2025
Chronicle Pharmabiz
HC appoints team to conduct inspection on Palamur Bio's facility
THE Delhi High Court (HC) has appointed a three-member inspection team to conduct fresh inspection at the facility of Telangana-based preclinical contract research organisation Palamur Biosciences in connection with the allegations raised by the People for the Ethical Treatment of Animals India (PETA India) pertaining to abuse and neglect of animals while carrying out experimentation.
2 mins
September 25, 2025
Listen
Translate
Change font size